
    
      A randomised, open-label, parallel group study to evaluate the management of
      rosiglitazone-related fluid retention by investigating the effect of diuretics on plasma
      volume in subjects with type 2 diabetes mellitus treated for twelve weeks with rosiglitazone
      4mg bd in addition to background anti-diabetic agents.
    
  